Clene Inc. (NASDAQ:CLNN) Receives Average Rating of “Moderate Buy” from Brokerages

Posted by Brian Himes on Jun 22nd, 2026

Shares of Clene Inc. (NASDAQ:CLNN – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $33.25.

Several research analysts have recently commented on CLNN shares. Weiss Ratings upgraded Clene from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. D. Boral Capital reissued a “buy” rating and issued a $23.00 target price on shares of Clene in a research note on Monday, May 4th. HC Wainwright reissued a “buy” rating and issued a $31.00 target price on shares of Clene in a research note on Monday, May 4th. Roth Mkm reissued a “buy” rating on shares of Clene in a research note on Thursday, May 14th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $48.00 target price on shares of Clene in a research note on Friday, March 13th.

Read Our Latest Analysis on Clene

Insiders Place Their Bets

In other Clene news, major shareholder Chidozie Ugwumba sold 73,296 shares of Clene stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $6.20, for a total transaction of $454,435.20. Following the sale, the insider directly owned 103,417 shares of the company’s stock, valued at approximately $641,185.40. The trade was a 41.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last quarter, insiders sold 327,677 shares of company stock worth $2,043,481. Insiders own 28.30% of the company’s stock.

Institutional Trading of Clene

Several large investors have recently bought and sold shares of CLNN. Jones Financial Companies Lllp bought a new stake in Clene during the 3rd quarter valued at approximately $29,000. Jane Street Group LLC bought a new stake in shares of Clene in the 2nd quarter worth approximately $47,000. State Street Corp boosted its position in shares of Clene by 138.4% in the 4th quarter. State Street Corp now owns 29,801 shares of the company’s stock worth $175,000 after purchasing an additional 17,300 shares in the last quarter. PEAK6 LLC bought a new stake in shares of Clene in the 4th quarter worth approximately $294,000. Finally, Lunt Capital Management Inc. boosted its position in shares of Clene by 2.5% in the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock worth $315,000 after purchasing an additional 1,250 shares in the last quarter. 23.28% of the stock is owned by institutional investors.

Clene Stock Performance

CLNN opened at $6.01 on Monday. The company has a market cap of $76.81 million, a P/E ratio of -1.88 and a beta of 0.91. The business’s 50-day moving average price is $6.30 and its 200-day moving average price is $5.76. Clene has a 12 month low of $3.25 and a 12 month high of $13.50.

Clene (NASDAQ:CLNN – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.05). The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.05 million. Equities research analysts forecast that Clene will post -1.58 earnings per share for the current fiscal year.

Clene Company Profile

(Get Free Report)

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).